Ahmad AL, Sanchez-Bornot J, Sotero RC, Coyle D, Idris Z, Faye I (2024) Towards improving Alzheimer’s intervention: a machine learning approach for biomarker detection through combining MEG and MRI pipelines. arXiv preprint arXiv:2408.04815. https://doi.org/10.48550/arXiv.2408.04815

Al-Ghraiybah NF, Wang J, Alkhalifa AE et al (2022) Glial cell-mediated neuroinflammation in Alzheimer’s disease. Int J Mol Sci. https://doi.org/10.3390/IJMS231810572

Article  PubMed  PubMed Central  Google Scholar 

Alhusaini M, Eissa N, Saad AK et al (2022) Revisiting preclinical observations of several histamine H3 receptor antagonists/inverse agonists in cognitive impairment, anxiety, depression, and sleep–wake cycle disorder. Front Pharmacol 13:861094. https://doi.org/10.3389/FPHAR.2022.861094/XML

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alvarez BD, Cavazos C, Morales CA et al (2022) Impact of specific serotonin receptor modulation on restricted repetitive behaviors. Front Behav Neurosci 16:1078983. https://doi.org/10.3389/FNBEH.2022.1078983

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alzheimer’s Drug Discovery Foundation (2020) Piromelatine: cognitive vitality report. Alzheimer’s Drug Discovery Foundation. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/Piromelatine-Cognitive-Vitality-For-Researchers.pdf. Accessed 23 Sept 2025

Andrews M, Tousi B, Sabbagh MN (2018) 5HT6 antagonists in the treatment of Alzheimer’s dementia: current progress. Neurol Ther 7:51–58. https://doi.org/10.1007/s40120-018-0095-y

Article  PubMed  PubMed Central  Google Scholar 

Askew KE, Beverley J, Sigfridsson E et al (2024) Inhibiting CSF1R alleviates cerebrovascular white matter disease and cognitive impairment. Glia 72:375–395. https://doi.org/10.1002/glia.24481

Article  CAS  PubMed  Google Scholar 

Avelar-Pereira B, Belloy ME, O’Hara R et al (2023) Decoding the heterogeneity of Alzheimer’s disease diagnosis and progression using multilayer networks. Mol Psychiatry 28:2423–2432. https://doi.org/10.1038/s41380-022-01886-z

Article  CAS  PubMed  Google Scholar 

Azam S, Haque MdE, Jakaria Md et al (2020) G-protein-coupled receptors in CNS: a potential therapeutic target for intervention in neurodegenerative disorders and associated cognitive deficits. Cells 9:506. https://doi.org/10.3390/cells9020506

Article  CAS  PubMed  PubMed Central  Google Scholar 

Badina AM, Ceyzériat K, Amossé Q et al (2025) Non-linear microglial, inflammatory and oligodendrocyte dynamics across stages of Alzheimer’s disease. Neurobiol Dis 211:106950. https://doi.org/10.1016/J.NBD.2025.106950

Article  CAS  PubMed  Google Scholar 

Bandaru N, Bukke SPN, Pedapati VMD et al (2025) Pathophysiology of Alzheimer’s disease: focus on H3 receptor modulators and their implications. Drugs Drug Candidates 4:22. https://doi.org/10.3390/ddc4020022

Article  Google Scholar 

Baronio D, Gonchoroski T, Castro K et al (2014) Histaminergic system in brain disorders: lessons from the translational approach and future perspectives. Ann Gen Psychiatry. https://doi.org/10.1186/S12991-014-0034-Y

Article  PubMed  PubMed Central  Google Scholar 

Bernis ME, Hakvoort C, Nacarkucuk E et al (2024) Neuroprotective effect of clemastine improved oligodendrocyte proliferation through the MAPK/ERK pathway in a neonatal hypoxia ischemia rat model. Int J Mol Sci. https://doi.org/10.3390/IJMS25158204

Article  PubMed  PubMed Central  Google Scholar 

Bezprozvanny I (2010) The rise and fall of Dimebon. Drug News Perspect 23:518. https://doi.org/10.1358/dnp.2010.23.8.1500435

Article  PubMed  PubMed Central  Google Scholar 

Bokobza C, Jacquens A, Guenoun D et al (2023) Targeting the brain 5-HT7 receptor to prevent hypomyelination in a rodent model of perinatal white matter injuries. J Neural Transm 130:281–297. https://doi.org/10.1007/s00702-022-02556-8

Article  CAS  PubMed  Google Scholar 

Bouter Y, Bouter C (2022) Selective serotonin reuptake inhibitor-treatment does not show beneficial effects on cognition or amyloid burden in cognitively impaired and cognitively normal subjects. Front Aging Neurosci 14:883256. https://doi.org/10.3389/fnagi.2022.883256

Article  CAS  PubMed  PubMed Central  Google Scholar 

Briones-Aranda A, Flores-Durán D, Romero-Nava R et al (2025) Role of 5-HT1A and 5-HT7 receptors in memory regulation and the importance of their coexpression: A systematic review. Biomol 15:762. https://doi.org/10.3390/BIOM15060762

Article  CAS  Google Scholar 

Carthy E, Ellender T (2021) Histamine, neuroinflammation and neurodevelopment: a review. Front Neurosci 15:680214. https://doi.org/10.3389/fnins.2021.680214

Article  PubMed  PubMed Central  Google Scholar 

Cerneckis J, Shi Y (2023) Myelin organoids for the study of Alzheimer’s disease. Front Neurosci. https://doi.org/10.3389/FNINS.2023.1283742

Article  PubMed  PubMed Central  Google Scholar 

Chao F-L, Zhang Y, Zhang L et al (2020) Fluoxetine promotes hippocampal oligodendrocyte maturation and delays learning and memory decline in APP/PS1 mice. Front Aging Neurosci 12:627362. https://doi.org/10.3389/fnagi.2020.627362

Article  CAS  PubMed  Google Scholar 

Chen Y, Zhen W, Guo T et al (2017) Histamine receptor 3 negatively regulates oligodendrocyte differentiation and remyelination. PLoS ONE 12:e0189380. https://doi.org/10.1371/JOURNAL.PONE.0189380

Article  PubMed  PubMed Central  Google Scholar 

Chen JF, Wang F, Huang NX et al (2022) Oligodendrocytes and myelin: Active players in neurodegenerative brains? Dev Neurobiol 82:160–174. https://doi.org/10.1002/DNEU.22867;PAGE:STRING:ARTICLE/CHAPTER

Article  PubMed  Google Scholar 

Chen Y, Wang Y, Song Z et al (2023) Abnormal white matter changes in Alzheimer’s disease based on diffusion tensor imaging: a systematic review. Ageing Res Rev. https://doi.org/10.1016/j.arr.2023.101911

Cheng L, Liu J, Chen Z (2021) The histaminergic system in neuropsychiatric disorders. Biomolecules 11:1345. https://doi.org/10.3390/biom11091345

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng F, Wang F, Tang J et al (2024) Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease. Cell Rep Med 5:101379. https://doi.org/10.1016/j.xcrm.2023.101379

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho H, Myung J, Suh HS, Kang H-Y (2018) Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis. Osteoporos Int 29:2163–2170. https://doi.org/10.1007/s00198-018-4564-z

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov (2016) Study NCT02615002. Available at: https://clinicaltrials.gov/study/NCT02615002. Accessed 23 Sept 2025

ClinicalTrials.gov (2022) Study NCT05267535. Available at: https://clinicaltrials.gov/study/NCT05267535. Accessed 23 Sept 2025

ClinicalTrials.gov (2025) Study NCT06159673. Available at: https://clinicaltrials.gov/study/NCT06159673. Accessed 6 Aug 2025

Cree BAC, Niu J, Hoi KK et al (2018) Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury. Brain 141:85–98. https://doi.org/10.1093/BRAIN/AWX312

Article  PubMed  Google Scholar 

Cummings JL, Tong G, Ballard C (2019) Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis 67:779–794. https://doi.org/10.3233/JAD-180766

Article  PubMed  PubMed Central  Google Scholar 

Cummings JL, Osse AML, Kinney JW (2023) Alzheimer’s disease: novel targets and investigational drugs for disease modification. Drugs 83(15):1387–1408. https://doi.org/10.1007/S40265-023-01938-W

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cummings J, Zhou Y, Lee G et al (2024) Alzheimer’s disease drug development pipeline: 2024. Alzheimer's Dement: Transl Res Clin Interv 10:e12465. https://doi.org/10.1002/TRC2.12465

Cummings JL, Zhou Y, Stone AV et al (2025) Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders. Nat Commun 16(1):1–10. https://doi.org/10.1038/S41467-025-56690-4